TrialJournal of the International AIDS Society2017

Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study.

Pedro Cahn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.